The pharmacokinetics of oral CdA (0.24 mg/kg) was studied in 4 patients (1 with hairy cell leukaemia and 3 with B-cell chronic lymphocytic leukaemia) to determine any effect of food and fasting with and without omeprazole.
Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting. The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake. Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C.V. 0.26 with and C.V. 0.27 without).
In conclusion, there was a small, though not statistically significant reduction in the bioavailability of CdA after food intake. Omeprazole did not significantly improve the bioavailability of CdA.
Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA (1985) Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75: 377–383PubMedCrossRefGoogle Scholar
Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 322: 1117–1121PubMedCrossRefGoogle Scholar
Saven A, Carrera CJ, Beutler E, Carson E, Prio LD (1991) 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia Lymphoma 5 [Suppl]: 133–138Google Scholar
Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Complete response to 2-chloro-deoxyadenosine (CdA) in B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 327: 1056–1061PubMedCrossRefGoogle Scholar
Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD (1992) 2-chloro-deoxyadenosine treatment of lowgrade lymphomas. J Clin Oncol 10: 371–377PubMedGoogle Scholar
Santana VM, Mirro J Jr, Harwood FC, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-chloro-deoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10: 363–370Google Scholar
Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in human. Cancer Res 51: 5570–5572PubMedGoogle Scholar
Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans; Alternative routes af administration. J Clin Oncol, 10: 1514–1518PubMedGoogle Scholar
Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Nat Acad Sci USA 89: 2970–2974PubMedCrossRefGoogle Scholar
Kazimierczuk Z, Cottam HB, Ravankar GR et al. (1984) Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosine and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Chem Soc 106: 6379–6382CrossRefGoogle Scholar